Hypogonadism in male patients with cancer

Cancer

Volumn 106, Issue 12, 2006, Pages 2583-2591

  Garcia, Jose M ^a   Li, Huiling ^a   Mann, Douglas ^a   Epner, Daniel ^a   Hayes, Teresa G ^a   Marcelli, Marco ^a   Cunningham, Glenn R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgens; Cachexia; Cytokines; Ghrelin; Insulin like growth factor 1; Interleukin 8; Sex hormone binding globulin; Testosterone; Tumor necrosis factor

Indexed keywords

ANDROGEN; CYTOKINE; GHRELIN; INTERLEUKIN 6; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APPETITE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CACHEXIA; CANCER PATIENT; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MUSCLE MASS; PRIORITY JOURNAL; RELIABILITY; VISUAL ANALOG SCALE;

AGED; APPETITE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; HYPOGONADISM; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PEPTIDE HORMONES; PROSTATIC NEOPLASMS; SERUM ALBUMIN; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745213399     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21889     Document Type: Article

References (59)

1. Bruera E, Carraro S, Roca E, Cedaro L, Chacon R. Association between malnutrition and caloric intake, emesis, psychological depression, glucose taste, and tumor mass. Cancer Treat Rep. 1984;68:873-876.
2. MacDonald N, Alexander HR, Bruera E. Cachexia-anorexia-asthenia. J Pain Symptom Manage. 1995;10:151-155.
3. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 2005;37:1084-1104.
4. Chatterjee R, Kottaridis PD, McGarrigle HH, Linch DC. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant. 2002;29:607-610.
5. Llobera J, Esteva M, Rifa J, et al. Terminal cancer, duration and prediction of survival time. Eur J Cancer. 2000;36:2036-2043.
6. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am. 2002;16:589-617.
7. Hijazi RA, Cunningham GR. Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med. 2005;56:117-137.
8. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004; 61:162-167.
9. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90:2920-2926.
10. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862-871.
11. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr., Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211-1216.
12. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11:279-292.
13. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun. 2002;293: 560-565.
14. Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol. 2002;543(Pt 1):379-386.
15. Tsigos C, Papanicolaou DA, Kyrou I, Raptis SA, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on the pituitary-testicular axis. J Interferon Cytokine Res. 1999;19:1271-1276.
16. Crown AL, Cottle K, Lightman SL, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf). 2002;56:723-733.
17. Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study. J Clin Endocrinol Metab. 1995;80:2082-2087.
18. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998;83:1886-1892.
19. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269(5 Pt 1):E820-E826.
20. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
21. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18:621-645.
22. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85:4908-4911.
23. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.
24. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003;9: 774-778.
25. Furuta M, Funabashi T, Kimura F. Intracerebroventricular administration of ghrelin rapidly suppresses pulsatile luteinizing hormone secretion in ovariectomized rats. Biochem Biophys Res Commun. 2001;288:780-785.
26. Fernandez-Fernandez R, Tena-Sempere M, Aguilar E, Pinilla L. Ghrelin effects on gonadotropin secretion in male and female rats. Neurosci Lett. 2004;362:103-107.
27. [No authors listed.] Management of cancer pain: adults. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 1994(9):1-29.
28. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6-9.
29. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164-2171.
30. Heedman PA, Strang P. Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res. 2001;21(6A):4077-4082.
31. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
32. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801-810.
33. Miller KK, Rosner W, Lee H, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89:525-533.
34. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
35. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
36. Daughaday WH, Kapadia M, Mariz I. Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay. J Lab Clin Med. 1987;109:355-363.
37. Engstrom BE, Karlsson FA, Wide L. Marked gender differences in ambulatory morning growth hormone values in young adults. Clin Chem. 1998;44(6 Pt 1):1289-1295.
38. Lewis RJ, Bessen HA. Statistical concepts and methods for the reader of clinical studies in emergency medicine. J Emerg Med. 1991;9:221-232.
39. Davidoff F, Godlee F, Hoey J, et al. Uniform requirements for manuscripts submitted to biomedical journals. J Am Osteopath Assoc. 2003;103:137-149.
40. Lissoni P, Barni S, Ardizzoia A, et al. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1. Tumori. 1995;81:261-264.
41. Svartberg J, von Muhlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol. 2004;19:657-663.
42. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KC. Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr. 1998;128: 1355-1360.
43. van der Poll T, Romijn JA, Endert E, Sauerwein HP. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism. 1993;42:303-307.
44. Todd BD. Pancreatic carcinoma and low serum testosterone; a correlation secondary to cancer cachexia? Eur J Surg Oncol. 1988;14:199-202.
45. Svartberg J, Midtby M, Bonaa KH, Sundsfjord J, Joakimsen RM, Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol 2003;149:145-152.
46. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer. 2001;91:1297-1303.
47. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7:363-369.
48. Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613-621.
49. Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage. 1994;9:126-131.
50. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215-2222.
51. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251-254.
52. Azizi F, Vagenakis AG, Longcope C, Ingbar SH, Braverman LE. Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids. 1973;22:467-472.
53. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100: 851-858.
54. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf). 2003;58:710-717.
55. Pagotto U, Gambineri A, Pelusi C, et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003;88:4139-4143.
56. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85:60-65.
57. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601-E607.
58. Wang GM, O'Shaughnessy PJ, Chubb C, Robaire B, Hardy MP. Effects of insulin-like growth factor I on steroidogenic enzyme expression levels in mouse Leydig cells. Endocrinology. 2003;144:5058-5064.
59. Chuzel F, Clark AM, Avallet O, Saez JM. Transcriptional regulation of the lutropin/human choriogonadotropin receptor and three enzymes of steroidogenesis by growth factors in cultured pig Leydig cells. Eur J Biochem. 1996;239:8-16.